PaulDiSilvestroMD

Obstetrics & Gynecology • Providence, RI

General Obstetrics, Gynecologic Oncology

Associate Professor, Obstetrics and Gynecology, Brown University Program in Medicine

Join to view full profile

Dr. DiSilvestro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. DiSilvestro's full profile

Already have an account?

Office
101 Dudley St
Providence, RI 02905
Phone+1 401-453-7520

Education & Training

University of Oklahoma Health Sciences CenterFellowship, Gynecologic Oncology, 1996 - 1999
Women and Infants Hospital of Rhode Island/Brown UniversityResidency, Obstetrics and Gynecology, 1990 - 1994
University of Vermont College of MedicineClass of 1990

Certifications & Licensure

MA State Medical License 1996 - 2026
RI State Medical License 1991 - 2026
CT State Medical License 2003 - 2025
NY State Medical License 1999 - 2004
OK State Medical License 1996 - 1999
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 3
Doxil and Gemcitabine in Recurrent Ovarian Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements, Danielle Enserro, Kyle C Strickland, Rebecca Previs, Daniela Matei
Gynecologic Oncology. 2025-01-23
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small
Journal of Clinical Oncology. 2024-12-19
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Omali Pitiyarachchi, Peter J Ansell, Robert L Coleman, Minh H Dinh, Laura Holman
Gynecologic Oncology. 2024-08-01

Journal Articles

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Paul DiSilvestro, Carol Aghajanian, The New England Journal of Medicine

Other

Adjuvant treatment of high-risk endometrial cancers
DiSilvestro PA, Fleming G
http://www.uptodate.com/contents/adjuvant-treatment-of-high-risk-endometrial-cancers
UpToDate, Wolters Kluwer Health - 2012-11-13

Press Mentions

The Challenges with Using Targeted Therapies in Ovarian Cancer SpaceMarch 25th, 2023
SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 25th, 2023
Key Advances and Advocacy Are Themes at SGO Annual MeetingMarch 21st, 2023
Join now to see all